<DOC>
	<DOCNO>NCT00068978</DOCNO>
	<brief_summary>This study evaluate test design measure immune system responses HIV HIV vaccine .</brief_summary>
	<brief_title>Analysis Immune Responses HIV Vaccines</brief_title>
	<detailed_description>Assays HIV-specific human CD4 CD8 T cell immunity need order evaluate immune response HIV vaccine . Such assay robust , reproducible , amenable high throughput analysis clinical specimen . Cytokine flow cytometry ( CFC ) assay reliably specifically detect human CD4 CD8 T cell responses AIDS-related opportunistic infection , include cause cytomegalovirus , Mycobacterium tuberculosis , Mycobacterium avium complex , cryptococcus , human papillomavirus . The purpose study devise evaluate similar CFC assay detection quantitation CD4 CD8 T cell response HIV . This study evaluate `` Gag-IFNg CFC '' assay compare result assay result assay immune phenotype function long-term nonprogressors , untreated patient progressive HIV disease , recipient candidate HIV vaccine . The study also examine HIV-specific immune response HIV infect individual appear exhibit significant immune protection HIV disease . Participants study draw study currently underway . As part study , participant regular blood test . Blood sample study use study . No participant directly enrol study .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Blood sample 5 cohort HIV infect individual 2 cohort HIV uninfected individual evaluate . Varying stage HIV disease represent cohort , include : Individuals expose seroconverted Individuals recently seroconverted HAARTtreated patient receive immune modulators IL2 therapeutic immunization HAARTtreated patient undergo structured treatment interruption HAARTtreated patient durable suppression viremia HAARTtreated patient experience incomplete suppression viremia HAARTtreated patient follow careful drug adherence monitoring Longterm nonprogressors Untreated progressors</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>HIV Seronegativity</keyword>
	<keyword>HIV Preventive Vaccine</keyword>
	<keyword>HIV Therapeutic Vaccine</keyword>
</DOC>